DMAA Files 8-K with Letter of Intent
Ticker: DMAA · Form: 8-K · Filed: 2026-04-08T09:00:33-04:00
Sentiment: neutral
Topics: acquisition, letter-of-intent, 8-k
TL;DR
DMAA signed an LOI for an acquisition - big moves ahead!
AI Summary
Drugs Made In America Acquisition Corp. (DMAA) filed an 8-K on April 8, 2026, disclosing a Letter of Intent (LOI) related to a potential acquisition. The filing includes Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits), with the LOI attached as Exhibit 10.1.
Why It Matters
This filing indicates that Drugs Made In America Acquisition Corp. is actively pursuing an acquisition, which could significantly alter its business operations and future prospects.
Risk Assessment
Risk Level: medium — The filing indicates a potential acquisition, which carries inherent risks and uncertainties until finalized.
Key Players & Entities
- Drugs Made In America Acquisition Corp. (company) — Filer
- 0002028614 (company) — CIK
- 2026-04-08 (date) — Filing Date
- EX-10.1 (document) — Letter of Intent Exhibit
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report other events (Item 8.01) and financial statements/exhibits (Item 9.01), specifically disclosing a Letter of Intent related to a potential acquisition.
When was this 8-K filing accepted by the SEC?
This 8-K filing was accepted by the SEC on April 8, 2026, at 09:00:33.
What specific exhibit is attached to this filing that is of interest?
Exhibit 10.1, a Letter of Intent, is attached to this filing.
What is the CIK number for Drugs Made In America Acquisition Corp.?
The CIK number for Drugs Made In America Acquisition Corp. is 0002028614.
What is the SIC code listed for this company?
The SIC code listed for this company is 6770, which falls under Blank Checks.
From the Filing
EDGAR Filing Documents for 0001213900-26-041284 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001213900-26-041284 Filing Date 2026-04-08 Accepted 2026-04-08 09:00:33 Documents 13 Period of Report 2026-04-07 Items Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits Interactive Data Document Format Files Seq Description Document Type Size 1 CURRENT REPORT ea0285527-8k_drugs.htm iXBRL 8-K 34716 2 LETTER OF INTENT ea028552701ex10-1.htm EX-10.1 18792 Complete submission text file 0001213900-26-041284.txt 290284 Data Files Seq Description Document Type Size 3 XBRL SCHEMA FILE dmaa-20260407.xsd EX-101.SCH 4169 4 XBRL DEFINITION FILE dmaa-20260407_def.xml EX-101.DEF 28927 5 XBRL LABEL FILE dmaa-20260407_lab.xml EX-101.LAB 38998 6 XBRL PRESENTATION FILE dmaa-20260407_pre.xml EX-101.PRE 27135 16 EXTRACTED XBRL INSTANCE DOCUMENT ea0285527-8k_drugs_htm.xml XML 8351 Mailing Address 420 LEXINGTON AVENUE SUITE 1402 NEW YORK NY 10170 Business Address 420 LEXINGTON AVENUE SUITE 1402 NEW YORK NY 10170 954-870-3104 Drugs Made In America Acquisition Corp. (Filer) CIK : 0002028614 (see all company filings) EIN. : 000000000 | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-42467 | Film No.: 26846647 SIC : 6770 Blank Checks (CF Office: 05 Real Estate & Construction)